GoodRx and Generic Insulin: What You Actually Pay in 2026

How GoodRx Works for Insulin Prescriptions

GoodRx functions as a pharmacy benefit aggregator: it negotiates group-buying discounts with pharmacy benefit managers and passes the reduced price to patients who present a GoodRx card or coupon at checkout. For insulin specifically, those discounts can be significant enough to undercut some insurance copays.

At CVS, Walgreens, Kroger, and Costco, GoodRx prices for a 10 mL vial of insulin lispro (generic Humalog) typically range from $21 to $88 depending on the chain and local contract. Insulin aspart (generic NovoLog, brand name Fiasp or NovoLog) runs $28, $95 per vial under GoodRx pricing at the same chains as of early 2026. These numbers shift monthly because pharmacy contracts are renegotiated on rolling cycles, so checking GoodRx.com on the day you fill a prescription is always the right move.

One important practical detail: you cannot combine GoodRx with insurance on the same transaction. The pharmacist must process the claim as cash-pay with the GoodRx coupon applied. If your insurance copay is already low, run both quotes before choosing. Some patients with high-deductible health plans find GoodRx cheaper during the first months of the year before meeting their deductible.

GoodRx does not require a membership fee for basic coupon use. The GoodRx Gold subscription ($9.99/month per individual, $19.99 for families) sometimes unlocks lower prices on specific drugs, but for insulin the free tier is usually competitive enough to evaluate first. Learn how GoodRx pricing is calculated at the FDA's drug pricing transparency page.

Which Generic Insulins Are Available in 2026

The FDA now lists more than eight interchangeable insulin biosimilars that pharmacists can substitute automatically without a new prescription. The FDA's current biosimilar product list is the definitive source.

Rapid-acting generics and biosimilars:

• Insulin lispro (Admelog, Lyumjev, and unbranded lispro): generic form of Humalog. Admelog was the first insulin biosimilar approved in the United States, cleared by the FDA in December 2017.
• Insulin aspart (unbranded aspart, Trurapi): generic and biosimilar forms of NovoLog/Fiasp.
• Insulin glulisine (Apidra generics): fewer biosimilar options as of 2026.

Long-acting generics and biosimilars:

• Insulin glargine (Basaglar, Semglee, Rezvoglar): Semglee received interchangeable designation in July 2021, the first interchangeable insulin biosimilar in U.S. history. Rezvoglar (Eli Lilly) launched at a 78% discount to Lantus list price.
• Insulin degludec (Tresiba): biosimilar pipeline exists but no FDA-approved interchangeable as of early 2026.
• Insulin detemir (Levemir generics): Novo Nordisk discontinued U.S. Levemir sales in 2024; watch the FDA biosimilar list for successors.

Over-the-counter traditional insulins at Walmart: ReliOn brand insulin at Walmart covers NPH (Novolin N), regular (Novolin R), and 70/30 mix at $24.88 per vial OTC. Walmart also carries ReliOn NovoLog (insulin aspart) at $72.88 per vial, sold OTC since 2021. These require no prescription but are not the same as modern rapid-acting analogs in terms of pharmacokinetic profile. Clinicians typically do not recommend switching between analog and human insulin without careful dose titration and patient education. The American Diabetes Association's Standards of Care in Diabetes 2024 addresses insulin selection in Section 9.

The IRA $35 Medicare Insulin Cap: What It Covers and What It Does Not

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month per covered insulin for Medicare Part D and Medicare Advantage drug plan enrollees, effective January 1, 2023. This is not an income-based benefit; every Medicare beneficiary qualifies automatically.

The $35 cap applies to each insulin product separately. If a patient uses both insulin glargine and insulin lispro, they pay up to $35 per insulin per month, which could total $70. The cap covers a 30-day supply regardless of how many pens or vials that requires. According to CMS data cited by the HHS Office of the Assistant Secretary for Planning and Evaluation, approximately 3.3 million Medicare beneficiaries used at least one insulin product in 2022, making the scope of this policy broad.

What the $35 cap does NOT cover:

• Commercial (private) insurance plans: the IRA did not mandate a cap for employer-sponsored or marketplace insurance. Several states have enacted their own caps ranging from $25 to $100 per month, but federal law does not require private insurers to comply.
• Uninsured patients: the cap is irrelevant without Part D enrollment.
• Inhaled insulin (Afrezza): not covered under the IRA insulin definition as of 2025.

For patients under 65 without Medicare, the manufacturer programs described in the next section are more relevant than the IRA cap.

Manufacturer Patient Assistance Programs in 2026

Each of the three major insulin manufacturers runs at least one cost-reduction program for commercially insured and uninsured patients. Eligibility rules differ, so check each program directly.

Eli Lilly: Insulin Value Program

Lilly's Insulin Value Program caps out-of-pocket costs at $35 per month for anyone, regardless of insurance status. Covered products include Humalog (lispro), Basaglar (glargine), Lyumjev (ultra-rapid lispro), and Rezvoglar. Patients can access up to three vials or two packs of pens per month at the $35 price by presenting the savings card at the pharmacy. The program does not require income verification. Lilly's program details are listed on their patient access page.

Lilly also runs a free insulin program for uninsured patients who meet income thresholds. Through the Lilly Insulin Assistance Program (LIAP), patients with household income at or below 400% of the federal poverty level may receive free Lilly insulin. The application is available through NeedyMeds or directly from Lilly.

Novo Nordisk: Patient Assistance and My$99Insulin

Novo Nordisk's My$99Insulin program allows uninsured or underinsured patients to purchase up to three vials or two packs of pens of most Novo Nordisk insulins for $99 per month. Covered insulins include Tresiba (degludec), Victoza-adjacent basal options, NovoLog (aspart), and Levemir inventory where available.

The Novo Nordisk Patient Assistance Program provides free insulin to patients who are uninsured, earning <400% of the federal poverty level, and not eligible for government coverage. Applications are processed within 2 to 4 weeks. Prescribers can initiate the application on behalf of their patients. See Novo Nordisk's assistance portal.

Sanofi: Insulins Valyou Savings Program

Sanofi's Insulins Valyou program caps costs at $99/month for uninsured patients and offers sliding-scale discounts for commercially insured patients whose out-of-pocket costs exceed a set threshold. Covered products include Lantus (glargine U-100), Toujeo (glargine U-300), Admelog (lispro), and Soliqua. Sanofi also partners with direct primary care clinics and federally qualified health centers (FQHCs) to distribute insulin at 340B pricing.

HealthRX Decision Framework: Choosing Your Insulin Savings Route in 2026

Use this sequential logic to find your cheapest option:

1. Medicare Part D enrollee? Pay no more than $35/month per insulin. Stop here.
2. Employer or ACA plan with low copay (<$35)? Use insurance. Check if your state has a separate cap (Colorado, California, and 24 other states have enacted caps as of 2025).
3. Commercially insured with high copay? Apply for the manufacturer savings card (Lilly, Novo, or Sanofi, depending on your insulin brand). Most approvals are instant electronic cards.
4. Uninsured, income <400% FPL? Apply for free insulin through manufacturer PAP programs or NeedyMeds.org.
5. Uninsured, any income, need insulin today? Walmart ReliOn NovoLog ($72.88/vial OTC) or Walmart ReliOn Novolin R ($24.88/vial OTC) provide same-day access. Lilly's $35 Insulin Value Program also applies in 24 hours at most pharmacies.
6. GoodRx as a fallback: If none of the above applies or produces a lower price, check GoodRx.com on the fill date and compare at 3+ nearby pharmacies.

Cost of CGMs in 2026 and How to Reduce It

Continuous glucose monitors have become standard of care for Type 1 diabetes and are increasingly recommended for Type 2 patients on insulin. The 2024 ADA Standards of Care recommend CGM for all adults with Type 1 diabetes and for adults with Type 2 diabetes using multiple daily injections or insulin pump therapy, citing evidence that CGM reduces HbA1c and hypoglycemia rates. In the DIAMOND trial (N=158), CGM use in adults with Type 1 diabetes on MDI produced a mean HbA1c reduction of 1.0 percentage point versus 0.4 percentage points in the SMBG group at 24 weeks (P<0.001). [1]

Without insurance, CGM costs vary substantially:

| Device | Sensor cost (monthly) | Transmitter/reader | |---|---|---| | Dexcom G7 | $289, $349 | Included in sensor pack | | Abbott FreeStyle Libre 3 | $89, $129 | Included (disposable) | | Medtronic Guardian 4 | $250, $310 | Separate, ~$200 upfront | | Abbott Lingo (OTC, no Rx) | $49, $89 | Included |

Abbott's FreeStyle Libre 3 is the most affordable prescription CGM and is now covered under Medicare Part B (not Part D) for Medicare patients meeting CGM criteria, including those on basal insulin only following a 2023 CMS coverage expansion. Medicare pays 80% of the approved amount; the patient owes roughly $0, $30/month with a supplemental policy. CMS coverage criteria for CGMs under Medicare are detailed here.

For commercially insured patients, prior authorization is common for CGMs. The key clinical criterion at most plans is insulin use or a history of hypoglycemia. Patients denied coverage should ask their provider to document hypoglycemia events and submit an appeal citing the ADA Standards of Care Section 7.

Abbott and Dexcom both offer manufacturer savings cards that reduce out-of-pocket costs to $0, $75 for commercially insured patients who qualify. Apply directly at the device manufacturer's website. Income-based programs exist but are less uniformly available than insulin assistance programs.

What Biosimilar Competition Has Done to Insulin Prices

The entry of biosimilar insulins since 2017 has pushed list prices down, though not always at the pharmacy counter. List price reductions only benefit patients who pay cash or have insurance plans structured around list price.

Eli Lilly's unilateral decision in March 2023 to cut list prices on its most-used insulins by 70% drew national attention. Humalog list price fell from $274.70 per vial to $66.40. Basaglar dropped to $44.59 per vial. Novo Nordisk followed with cuts to NovoLog (now $72 list) and Tresiba. Sanofi reduced Lantus to $130 per vial list price. These reductions matter most for uninsured patients paying cash without any discount program.

For insured patients, PBM formulary placement and rebate structures often mean the actual copay does not change even when list prices fall. A 2023 JAMA study found that among commercially insured insulin users, median out-of-pocket spending actually increased from 2014 to 2019 despite rising list prices, suggesting rebate capture by PBMs rather than patients. [2] That dynamic is beginning to shift as employer plans adopt pass-through pricing models, but progress is uneven.

The FDA's Purple Book tracks interchangeable biosimilar designations. An interchangeable designation means a pharmacist can substitute the biosimilar for the reference product without a new prescription from the prescriber. All Semglee (insulin glargine-yfgn) prescriptions written as "Lantus" can now be filled with Semglee automatically in states that allow biosimilar substitution.

Practical Tips for Filling Insulin Prescriptions in 2026

Ask your prescriber to write "substitution permitted" or leave the DAW (Dispense As Written) code blank. A DAW-0 code allows the pharmacist to dispense the least costly interchangeable biosimilar. A DAW-1 code locks the brand and blocks savings.

Compare GoodRx prices across at least three pharmacies before filling. A vial of insulin lispro that costs $88 at one CVS location may cost $24 at a nearby independent pharmacy using the same GoodRx group number. Distance is sometimes worth the savings on a 90-day supply.

Request a 90-day supply. Most plans and GoodRx contracts price 90-day fills proportionally lower per unit than 30-day supplies. The Lilly $35 Insulin Value Program also covers 90-day supplies at $35 per 90 days, not per 30 days, for patients who request it.

Use your state's pharmacy assistance program as a last resort. States including New York, California, Colorado, Minnesota, and Illinois maintain emergency insulin programs or prescription drug affordability boards that can provide short-term supply. Check your state health department's website or NeedyMeds.org's state programs list.

Do not abruptly switch insulin formulations without clinical guidance. Human insulin (Novolin R, Humulin R) has a slower onset and longer duration than rapid-acting analogs like lispro or aspart. Switching to OTC human insulin to save money requires meal timing adjustments and typically a lower correction factor. According to the ADA's 2024 Standards of Care, insulin regimen changes should include structured patient education and dose titration support. [3]

Key Safety Notes for Generic Insulin Use

Generic and biosimilar insulins are not chemically identical to their reference products at the molecular level, but the FDA's interchangeability standard requires demonstration of no clinically meaningful difference in safety or efficacy. The evidentiary bar is high.

Side effects for insulin lispro and insulin aspart are similar across branded and generic forms. Injection-site reactions (redness, lipohypertrophy, skin thickening) are the most common, occurring in roughly 2 to 3% of patients in clinical trials. More serious reactions include hypoglycemia, hypokalemia, and rare hypersensitivity. The FDA prescribing information for insulin lispro injection is available here.

Hypoglycemia remains the primary risk. The DEVOTE trial (N=7,637), which compared insulin degludec to insulin glargine U-100 in high-cardiovascular-risk Type 2 patients, found that degludec produced 40% fewer severe hypoglycemia events (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). [4] That trial used branded products, but the principle applies when evaluating any long-acting insulin switch: the agent matters, not just the cost.

Patients storing insulin properly extends supply and prevents waste. Unopened vials and pens should be refrigerated at 36°F, 46°F (2°C, 8°C). Once opened, most insulins are stable at room temperature (below 77°F/25°C) for 28 to 30 days. Insulin exposed to temperatures above 86°F should not be used.

Frequently Asked Questions